Kal Vista Pharmaceuticals, Inc. KALV
We take great care to ensure that the data presented and summarized in this overview for KalVista Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KALV
View all-
Vr Adviser, LLC New York, NY6.7MShares$104 Million18.68% of portfolio
-
Tang Capital Management LLC San Diego, CA4.94MShares$76.9 Million3.7% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.91MShares$76.4 Million2.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.89MShares$76.1 Million3.55% of portfolio
-
Vestal Point Capital, LP New York, NY4.75MShares$73.9 Million3.92% of portfolio
-
Capital World Investors Los Angeles, CA3.18MShares$49.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.95MShares$45.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.3MShares$35.8 Million0.0% of portfolio
-
Silverarc Capital Management, LLC1.7MShares$26.4 Million4.78% of portfolio
-
Woodline Partners LP San Francisco, CA1.62MShares$25.2 Million0.13% of portfolio
Latest Institutional Activity in KALV
Top Purchases
Top Sells
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Insider Transactions at KALV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
32,979
-8.19%
|
$494,685
$15.69 P/Share
|
Jul 09
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
30,250
-19.12%
|
$453,750
$15.69 P/Share
|
Jul 08
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+17.85%
|
-
|
Jul 08
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+27.5%
|
-
|
Jun 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,169
-2.22%
|
$100,366
$14.5 P/Share
|
Jun 06
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+4.62%
|
-
|
May 23
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,926
-1.92%
|
$21,186
$11.31 P/Share
|
May 23
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,146
-1.86%
|
$23,606
$11.31 P/Share
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.03%
|
-
|
May 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.16%
|
-
|
May 22
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,999
-3.16%
|
$109,989
$11.88 P/Share
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,317
-2.33%
|
$25,487
$11.88 P/Share
|
May 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,689
-2.38%
|
$29,579
$11.88 P/Share
|
May 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+6.84%
|
-
|
May 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+3.64%
|
-
|
May 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+5.25%
|
-
|
May 19
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,776
-2.54%
|
$30,536
$11.84 P/Share
|
May 19
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,808
-1.28%
|
$41,888
$11.84 P/Share
|
May 19
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,600
-2.65%
|
$28,600
$11.84 P/Share
|
May 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+5.57%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 289K shares |
---|---|
Grant, award, or other acquisition | 148K shares |
Open market or private purchase | 361K shares |
Open market or private sale | 203K shares |
---|